drugset / Trial / NCT02305563
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and effectiveness of ulocuplumab in combination with low dose cytarabine in the treatment of Newly Diagnosed Acute Myeloid Leukemia (AML).
Timeline
- Start
- 2015-01-27
- Primary completion
- 2019-06-04
- Completion
- 2019-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulocuplumab | Monoclonal antibody | — | — |
| Background | Cytarabine | Small molecule | — | — |